Which has stronger valuation & earnings, VCEL or IMVT?

Vericel has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 6.91 $16.52M $0.42 89.00 Immunovant N/A N/A -$505.61M -$2.78 N/A

Is VCEL or IMVT more profitable?

Vericel has a net margin of 7.35% compared to Immunovant's net margin of 0.00%. Vericel's return on equity of 6.41% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.35% 6.41% 4.61% Immunovant N/A -65.66% -59.88%

Does the media favor VCEL or IMVT?

In the previous week, Vericel had 1 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for Vericel and 5 mentions for Immunovant. Immunovant's average media sentiment score of 1.64 beat Vericel's score of 0.60 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, VCEL or LNTH?

Lantheus has higher revenue and earnings than Vericel. Lantheus is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 6.91 $16.52M $0.42 89.00 Lantheus $1.55B 4.22 $233.56M $4.15 24.15

Is VCEL or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Vericel's net margin of 7.35%. Lantheus' return on equity of 29.32% beat Vericel's return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.35% 6.41% 4.61% Lantheus 18.05% 29.32% 15.00%

Does the media favor VCEL or LNTH?

In the previous week, Vericel had 2 more articles in the media than Lantheus. MarketBeat recorded 6 mentions for Vericel and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.65 beat Vericel's score of 0.60 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, VCEL or KYMR?

Vericel has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 6.91 $16.52M $0.42 89.00 Kymera Therapeutics $39.21M 164.12 -$311.35M -$3.57 N/A

Does the media favor VCEL or KYMR?

In the previous week, Kymera Therapeutics had 3 more articles in the media than Vericel. MarketBeat recorded 9 mentions for Kymera Therapeutics and 6 mentions for Vericel. Kymera Therapeutics' average media sentiment score of 0.75 beat Vericel's score of 0.60 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VCEL or PTGX?

In the previous week, Vericel had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for Vericel and 5 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.23 beat Vericel's score of 0.60 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SYRE or VCEL?

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyre Therapeutics $890K 7,325.78 -$155.20M -$2.08 N/A Vericel $276.26M 6.91 $16.52M $0.42 89.00

Does the media refer more to SYRE or VCEL?

In the previous week, Spyre Therapeutics had 5 more articles in the media than Vericel. MarketBeat recorded 11 mentions for Spyre Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 0.60 beat Spyre Therapeutics' score of 0.26 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vericel (VCEL) Competitors

$37.38 +0.35 (+0.95%)

Closing price 04:00 PM Eastern

Extended Trading

$37.38 +0.00 (+0.01%)

As of 04:10 PM Eastern

Compare

VCEL vs. IMVT, LNTH, KYMR, PTGX, and SYRE

Should you buy Vericel stock or one of its competitors? MarketBeat compares Vericel with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vericel include Immunovant (IMVT), Lantheus (LNTH), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Vericel compare to Immunovant?

Vericel (NASDAQ:VCEL) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

In the previous week, Vericel had 1 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for Vericel and 5 mentions for Immunovant. Immunovant's average media sentiment score of 1.64 beat Vericel's score of 0.60 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Vericel has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	6.91	$16.52M	$0.42	89.00
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Vericel currently has a consensus target price of $55.40, indicating a potential upside of 48.21%. Immunovant has a consensus target price of $37.33, indicating a potential upside of 19.73%. Given Vericel's stronger consensus rating and higher possible upside, analysts clearly believe Vericel is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Vericel has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Vericel has a net margin of 7.35% compared to Immunovant's net margin of 0.00%. Vericel's return on equity of 6.41% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Immunovant	N/A	-65.66%	-59.88%

47.1% of Immunovant shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vericel beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Vericel compare to Lantheus?

Vericel (NASDAQ:VCEL) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Vericel has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

In the previous week, Vericel had 2 more articles in the media than Lantheus. MarketBeat recorded 6 mentions for Vericel and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.65 beat Vericel's score of 0.60 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Lantheus shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Vericel's net margin of 7.35%. Lantheus' return on equity of 29.32% beat Vericel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Lantheus	18.05%	29.32%	15.00%

Vericel presently has a consensus price target of $55.40, suggesting a potential upside of 48.21%. Lantheus has a consensus price target of $101.86, suggesting a potential upside of 1.61%. Given Vericel's higher possible upside, equities analysts clearly believe Vericel is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Lantheus has higher revenue and earnings than Vericel. Lantheus is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	6.91	$16.52M	$0.42	89.00
Lantheus	$1.55B	4.22	$233.56M	$4.15	24.15

Summary

Lantheus beats Vericel on 10 of the 16 factors compared between the two stocks.

How does Vericel compare to Kymera Therapeutics?

Vericel (NASDAQ:VCEL) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Kymera Therapeutics had 3 more articles in the media than Vericel. MarketBeat recorded 9 mentions for Kymera Therapeutics and 6 mentions for Vericel. Kymera Therapeutics' average media sentiment score of 0.75 beat Vericel's score of 0.60 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel presently has a consensus price target of $55.40, suggesting a potential upside of 48.21%. Kymera Therapeutics has a consensus price target of $117.14, suggesting a potential upside of 49.73%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Vericel has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	6.91	$16.52M	$0.42	89.00
Kymera Therapeutics	$39.21M	164.12	-$311.35M	-$3.57	N/A

Vericel has a net margin of 7.35% compared to Kymera Therapeutics' net margin of -611.94%. Vericel's return on equity of 6.41% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Vericel has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Summary

Kymera Therapeutics beats Vericel on 8 of the 15 factors compared between the two stocks.

How does Vericel compare to Protagonist Therapeutics?

Vericel (NASDAQ:VCEL) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Vericel had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for Vericel and 5 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.23 beat Vericel's score of 0.60 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel currently has a consensus target price of $55.40, suggesting a potential upside of 48.21%. Protagonist Therapeutics has a consensus target price of $115.21, suggesting a potential upside of 8.93%. Given Vericel's higher probable upside, equities analysts clearly believe Vericel is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Vericel has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	6.91	$16.52M	$0.42	89.00
Protagonist Therapeutics	$46.02M	147.81	-$130.15M	-$1.81	N/A

Vericel has a net margin of 7.35% compared to Protagonist Therapeutics' net margin of -154.88%. Vericel's return on equity of 6.41% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Vericel has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Summary

Vericel beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Vericel compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Spyre Therapeutics presently has a consensus target price of $91.33, suggesting a potential upside of 21.65%. Vericel has a consensus target price of $55.40, suggesting a potential upside of 48.21%. Given Vericel's higher possible upside, analysts clearly believe Vericel is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,325.78	-$155.20M	-$2.08	N/A
Vericel	$276.26M	6.91	$16.52M	$0.42	89.00

Vericel has a net margin of 7.35% compared to Spyre Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.41% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Vericel	7.35%	6.41%	4.61%

Spyre Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market. Comparatively, Vericel has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 5 more articles in the media than Vericel. MarketBeat recorded 11 mentions for Spyre Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 0.60 beat Spyre Therapeutics' score of 0.26 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vericel beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCEL vs. The Competition

Export

Metric	Vericel	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.89B	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	89.00	18.83	24.65	23.63
Price / Sales	6.91	290.84	500.87	105.21
Price / Cash	66.66	120.20	43.05	54.72
Price / Book	5.33	8.00	10.43	6.70
Net Income	$16.52M	$23.89M	$3.56B	$337.26M
7 Day Performance	7.60%	-3.49%	-1.39%	-1.41%
1 Month Performance	11.72%	1.03%	0.86%	1.15%
1 Year Performance	-18.21%	34.39%	19.42%	22.61%

Vericel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCEL Vericel	3.4157 of 5 stars	$37.38 +0.9%	$55.40 +48.2%	-15.5%	$1.89B	$276.26M	89.00	300	News Coverage
IMVT Immunovant	3.753 of 5 stars	$32.86 -1.3%	$37.33 +13.6%	+94.0%	$6.75B	N/A	N/A	120	Positive News
LNTH Lantheus	3.1939 of 5 stars	$97.13 -2.2%	$101.86 +4.9%	+20.1%	$6.47B	$1.55B	23.40	1,193
KYMR Kymera Therapeutics	2.3381 of 5 stars	$78.47 -3.6%	$118.10 +50.5%	+63.1%	$6.45B	$51.48M	N/A	170	News Coverage Analyst Forecast
PTGX Protagonist Therapeutics	1.8086 of 5 stars	$94.92 -4.7%	$115.21 +21.4%	+90.1%	$6.40B	$74.06M	N/A	120	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCEL) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vericel (VCEL) Competitors

VCEL vs. IMVT, LNTH, KYMR, PTGX, and SYRE

How does Vericel compare to Immunovant?

Summary

How does Vericel compare to Lantheus?

Summary

How does Vericel compare to Kymera Therapeutics?

Summary

How does Vericel compare to Protagonist Therapeutics?

Summary

How does Vericel compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vericel (VCEL) Competitors

VCEL vs. IMVT, LNTH, KYMR, PTGX, and SYRE

How does Vericel compare to Immunovant?

Does the media favor VCEL or IMVT?

Which has stronger valuation & earnings, VCEL or IMVT?

Do analysts recommend VCEL or IMVT?

Which has more volatility & risk, VCEL or IMVT?

Is VCEL or IMVT more profitable?

Do insiders & institutionals believe in VCEL or IMVT?

Summary

How does Vericel compare to Lantheus?

Which has more volatility and risk, VCEL or LNTH?

Does the media favor VCEL or LNTH?

Do insiders and institutionals have more ownership in VCEL or LNTH?

Is VCEL or LNTH more profitable?

Do analysts recommend VCEL or LNTH?

Which has better valuation & earnings, VCEL or LNTH?

Summary

How does Vericel compare to Kymera Therapeutics?

Does the media favor VCEL or KYMR?

Do analysts recommend VCEL or KYMR?

Which has better valuation & earnings, VCEL or KYMR?

Is VCEL or KYMR more profitable?

Which has more risk and volatility, VCEL or KYMR?

Summary

How does Vericel compare to Protagonist Therapeutics?

Do insiders and institutionals have more ownership in VCEL or PTGX?

Does the media prefer VCEL or PTGX?

Do analysts recommend VCEL or PTGX?

Which has higher earnings and valuation, VCEL or PTGX?

Is VCEL or PTGX more profitable?

Which has more risk and volatility, VCEL or PTGX?

Summary

How does Vericel compare to Spyre Therapeutics?

Do analysts rate SYRE or VCEL?

Which has better valuation and earnings, SYRE or VCEL?

Is SYRE or VCEL more profitable?

Which has more risk and volatility, SYRE or VCEL?

Do institutionals and insiders have more ownership in SYRE or VCEL?

Does the media refer more to SYRE or VCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools